Thyssenkrupp Raises 2026 Profit Outlook as Steel and Materials Units Strengthen 
Paramount Weighs CNN Sale as $110B Warner Bros. Discovery Deal Faces Antitrust Fight 
Ford to Move Some Lincoln Production From China to U.S. in 2030 
ANZ Home Loan Applications Drop 12% After Australia Property Tax Changes 
Alphabet’s SpaceX Investment Soars 100-Fold to $94 Billion 
Stripe, Advent Reportedly Pursue $53 Billion PayPal Takeover 
Super Micro Stock Jumps 19% as AI Server Demand Drives Strong 2027 Outlook 
J.P. Morgan Upgrades SanDisk, Sets $2,250 Price Target on AI NAND Growth 
Anthropic Eyes $6B Decart AI Acquisition Ahead of Mega IPO 
Tesla Roadster Reveal Could Feature SpaceX Thrusters in August 
Cisco Forecasts Strong Fiscal 2027 Growth as AI Networking Demand Surges 
Bernstein Picks BYD and Xiaomi as Top China EV Stocks Despite Weaker Demand 
Paramount Skydance Clears Regulatory Hurdles for Warner Bros. Discovery Deal 
Lenovo Revenue Surges 43% as AI Demand Drives Record First-Quarter Growth 
Antofagasta Shares Drop 5% as Miner Cuts 2026 Copper Production Forecast 
SMIC Shares Rally as Q2 Profit Surges 262% on Strong Chip Demand 
Add as a preferred source on Google
RESEARCH TRIANGLE PARK, N.C., May 09, 2017 -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) announced today that executives from the Company are scheduled to provide a corporate summary and update regarding the Company’s clinical programs at the Bank of America Merrill Lynch Health Care Conference in Las Vegas on Tuesday, May 16, 2017 at 5:00 p.m. Pacific Time.
Links to a live audio webcast and replay of the presentation may be accessed on the BioCryst website events page at http://investor.shareholder.com/biocryst/events.cfm.
About BioCryst Pharmaceuticals
BioCryst Pharmaceuticals designs, optimizes and develops novel small molecule drugs that block key enzymes involved in rare diseases. BioCryst has several ongoing development programs: BCX7353 and other second generation oral inhibitors of plasma kallikrein for hereditary angioedema, and galidesivir, a broad spectrum viral RNA polymerase inhibitor that is a potential treatment for filoviruses. RAPIVAB® (peramivir injection), a viral neuraminidase inhibitor for the treatment of influenza, is BioCryst's first approved product and has received regulatory approval in the U.S., Canada, Japan, Taiwan and Korea. Post-marketing commitment development activities for RAPIVAB are ongoing, as well as activities to support regulatory approvals in other territories. For more information, please visit the Company's website at www.BioCryst.com.
This press release contains forward-looking statements, including statements regarding future results and achievements. These statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performances or achievements expressed or implied by the forward-looking statements. Please refer to the documents BioCryst files periodically with the SEC and located at http://investor.shareholder.com/biocryst/sec.cfm.
BCRXW
CONTACT: Thomas Staab, BioCryst Pharmaceuticals, +1-919-859-7910
